Ticker >

Ajanta Pharma share price

Ajanta Pharma Ltd.

NSE: AJANTPHARM BSE: 532331 SECTOR: Pharmaceuticals & Drugs  97k   509   51

3344.90
+45.00 (1.36%)
NSE: Today, 11:34 AM

Price Summary

Today's High

₹ 3388.3

Today's Low

₹ 3263.05

52 Week High

₹ 3485

52 Week Low

₹ 1650.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

41781.85 Cr.

Enterprise Value

41718.79 Cr.

No. of Shares

12.49 Cr.

P/E

50.27

P/B

11.47

Face Value

₹ 2

Div. Yield

1.52 %

Book Value (TTM)

₹  291.7

CASH

63.06 Cr.

DEBT

0 Cr.

Promoter Holding

66.26 %

EPS (TTM)

₹  66.55

Sales Growth

16.41%

ROE

24.26 %

ROCE

33.15%

Profit Growth

44.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ajanta Pharma Ltd.

Met XL Softdrops Sunstop Kamagra Melacare Cinod Feburic Forticord Zaha Ilapro

Index Presence

The company is present in 21 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.41%
3 Year13.46%
5 Year17.51%

Profit Growth

1 Year44.48%
3 Year6.11%
5 Year15.56%

ROE%

1 Year24.26%
3 Year21.82%
5 Year21.98%

ROCE %

1 Year33.15%
3 Year28.39%
5 Year29.24%

Debt/Equity

0

Price to Cash Flow

56.82

Interest Cover Ratio

162.3162

CFO/PAT (5 Yr. Avg.)

0.868625081574601

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 66.26 11.17
Jun 2024 66.27 11.57
Mar 2024 66.21 12.26
Dec 2023 66.21 12.33
Sep 2023 66.21 12.43
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 21.8227398803044% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.3921139897195% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 162.3162.
  • The Company has been maintaining an effective average operating margins of 26.5557880142132% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 7.50989999999999 days.
  • Company has a healthy liquidity position with current ratio of 3.8666.

 Limitations

  • The company has shown a poor profit growth of 6.11149666809405% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.4634235238538% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 32.9521.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 1014.58 945.18 1085.29 926.07 1077.27
Total Expenditure 737.68 671.53 758.11 698.92 761.44
Operating Profit 276.9 273.65 327.18 227.15 315.83
Other Income 31.46 52.16 13.73 33.68 28.37
Interest 0.75 2.27 2.36 1.42 0.72
Depreciation 32.24 33.04 33.41 33.47 32.92
Exceptional Items 0 0 0 0 0
Profit Before Tax 275.37 290.5 305.14 225.94 310.56
Tax 63.33 78.14 84.99 63.25 74.53
Profit After Tax 212.04 212.36 220.15 162.69 236.03
Adjusted EPS (Rs) 16.78 16.81 17.42 12.88 18.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2196.42 2718.59 3140.64 3411.27 3971.12
Total Expenditure 1663.64 1801.68 2249.75 2711.99 2851.69
Operating Profit 532.78 916.91 890.89 699.28 1119.43
Other Income 184.2 103.57 139.73 132.75 116.48
Interest 9.1 6.9 9.12 5.23 6.8
Depreciation 91.29 111.49 120.96 126.95 132.16
Exceptional Items -3.92 0 0 0 0
Profit Before Tax 612.67 902.09 900.54 699.85 1096.95
Tax 171.54 226.45 180.68 141.13 289.71
Net Profit 441.13 675.64 719.86 558.72 807.24
Adjusted EPS (Rs.) 33.71 52.07 56.2 44.38 64.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 17.54 17.39 17.17 25.27 25.27
Total Reserves 2443.76 2867.59 3152.01 3221.18 3388.3
Borrowings 0 0 0 0 0
Other N/C liabilities 252.27 321.18 338.33 272.9 174.17
Current liabilities 614.3 706.28 469.7 907.84 629.19
Total Liabilities 3327.87 3912.44 3977.21 4427.19 4217.44
Assets
Net Block 1439.93 1509.89 1483.91 1484.01 1464.89
Capital WIP 131.06 108.19 152.86 209.47 256.45
Intangible WIP 0 0 0 0 0
Investments 18.63 17.89 42.99 42.99 37.09
Loans & Advances 165.33 230.52 226.15 134.68 12.97
Other N/C Assets 18.48 19.55 14.29 12.77 13.22
Current Assets 1554.44 2026.4 2057.01 2543.27 2432.82
Total Assets 3327.87 3912.44 3977.21 4427.19 4217.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 612.67 902.09 900.54 699.85 1096.95
Adjustment -36.6 37.07 55.58 79.34 49.31
Changes in Assets & Liabilities -136.66 -274.26 -220.31 82.66 -158.63
Tax Paid -138.53 -197.91 -193.47 -125.56 -252.28
Operating Cash Flow 300.88 466.99 542.34 736.29 735.35
Investing Cash Flow -115.91 -162.68 -66.04 -501.31 105.02
Financing Cash Flow -134 -268.9 -457.3 -105.12 -1047.7
Net Cash Flow 50.97 35.41 19 129.86 -207.33

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 66.21 66.21 66.21 66.27 66.26
aayush m agrawal 0.02 0.02 0.02 0.02 0.02
aayush m agrawal, trustee... 11.31 11.31 11.31 11.30 11.30
gabs investments pvt ltd 10.00 10.00 10.00 10.08 10.08
ganga exports being repre... 2.68 2.68 2.68 2.68 2.68
rajesh m agrawal, trustee... 14.48 14.48 14.48 14.48 14.47
ravi p agrawal 0.23 0.23 0.23 0.23 0.23
ravi p agrawal, trustee r... 13.01 13.01 13.01 13.01 13.00
yogesh m agrawal, trustee... 14.48 14.48 14.48 14.48 14.47
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 33.79 33.79 33.79 33.73 33.74
aditya birla sun life tru... - - - - 1.05
canara robeco mutual fund... - - - - 1.03
hdfc large and mid cap fu... - - 1.04 1.13 1.54
investor education and pr... - 0.09 - - 0.09
kotak small cap fund - 1.23 1.24 1.24 1.24
llp 0.05 0.04 0.03 0.03 0.03
nippon life india trustee... 3.16 3.12 2.99 3.04 2.98
tata aia life insurance c... 1.64 1.64 1.65 1.67 1.34
uti flexi cap fund 3.66 3.16 3.08 3.03 2.95
investor education and pr... 0.09 - 0.09 0.09 -
invesco india contra fund... - 1.03 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Ajanta Pharma informs about disclosure 10 Sep 2024, 2:10PM Ajanta Pharma informs about loss of share certificate23 Aug 2024, 2:13PM Ajanta Pharma informs about disclosure21 Aug 2024, 5:29PM Ajanta Pharma informs about participation in investor conference8 Aug 2024, 2:25PM Ajanta Pharma reports 18% rise in Q1 consolidated net profit30 Jul 2024, 5:19PM Ajanta Pharma - Quaterly Results30 Jul 2024, 3:01PM Ajanta Pharma - Quaterly Results30 Jul 2024, 3:01PM Ajanta Pharma - Quaterly Results30 Jul 2024, 3:01PM Ajanta Pharma informs about board meeting17 Jul 2024, 3:14PM Ajanta Pharma informs about compliances-certificate11 Jul 2024, 2:24PM Ajanta Pharma informs about annual report and BRSR 18 Jun 2024, 5:34PM Ajanta Pharma informs about newspapers publication 17 Jun 2024, 4:29PM Ajanta Pharma informs about disclosure4 Jun 2024, 12:37PM Ajanta Pharma - Quaterly Results2 May 2024, 4:39PM Ajanta Pharma - Quaterly Results2 May 2024, 4:39PM Ajanta Pharma - Quaterly Results2 May 2024, 4:39PM Ajanta Pharma informs about compliance certificate15 Apr 2024, 4:53PM Ajanta Pharma informs about disclosure 30 Mar 2024, 3:27PM Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma - Quaterly Results31 Jan 2024, 4:12PM Ajanta Pharma submits intimation of record date 25 Jan 2024, 12:53PM Ajanta Pharma informs about update on board meeting 25 Jan 2024, 10:58AM Ajanta Pharma informs about loss of share certificate19 Dec 2023, 1:39PM Ajanta Pharma informs about loss of share certificate15 Dec 2023, 2:12PM Ajanta Pharma informs about disclosure 15 Dec 2023, 12:22PM Ajanta Pharma informs about revised disclosure15 Dec 2023, 12:14PM Ajanta Pharma informs about disclosures24 Nov 2023, 5:05PM Ajanta Pharma informs about loss of share certificate22 Nov 2023, 10:43AM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma - Quaterly Results31 Oct 2023, 2:15PM Ajanta Pharma informs about board meeting19 Oct 2023, 3:17PM Ajanta Pharma informs about loss of share certificate27 Sep 2023, 11:32AM Ajanta Pharma informs about newspaper publication 4 Sep 2023, 11:06AM Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules30 Aug 2023, 6:15PM Ajanta Pharma informs about investor meetings17 Aug 2023, 10:12AM Ajanta Pharma informs about details of loss of certificate 7 Aug 2023, 4:20PM Ajanta Pharma informs about outcome of board meeting27 Jul 2023, 4:51PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma - Quaterly Results27 Jul 2023, 3:52PM Ajanta Pharma informs about conference call24 Jul 2023, 12:08PM Ajanta Pharma informs about board meeting24 Jul 2023, 12:04PM Ajanta Pharma informs about disclosure21 Jul 2023, 2:44PM Ajanta Pharma inks partnership with Credible Innovations11 Jul 2023, 3:12PM Ajanta Pharma to enhance presence across select geographies in Asia, Africa3 Jul 2023, 12:09PM USFDA completes inspection at Ajanta Pharma’s Dahej formulation facility26 Jun 2023, 10:05AM Ajanta Pharma informs about updates 26 Jun 2023, 9:33AM Ajanta Pharma informs about newspaper publication 19 Jun 2023, 10:40AM

Ajanta Pharma Stock Price Analysis and Quick Research Report. Is Ajanta Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ajanta Pharma and its performance over the period of time. Ajanta Pharma stock price today is Rs 3299.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ajanta Pharma cash from the operating activity was Rs 735.35 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ajanta Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ajanta Pharma , the EPS growth was 44.4803 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ajanta Pharma has OPM of 28.1892765768851 % which is a good sign for profitability.
     
  • ROE: Ajanta Pharma have a healthy ROE of 24.2638 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ajanta Pharma is Rs 3299.9. One can use valuation calculators of ticker to know if Ajanta Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Ajanta Pharma

Ajanta Pharma Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ajanta Pharma Ltd. is a pharmaceutical major that produces a diverse range of speciality and generic formulations. The company caters to healthcare needs across various therapeutic segments such as cardiovascular, dermatology, ophthalmology, pain management, and many others. As a long-term investor, knowing the ins and outs of a company is vital before investing in it. This article will provide an in-depth analysis of Ajanta Pharma Ltd.’s stocks based on several parameters.

Ajanta Pharma Ltd Share Price

Ajanta Pharma Ltd.’s share price is a key metric that is continuously monitored by traders and investors alike. The company is a part of the 'Pharmaceuticals - Indian' industry, which has seen immense growth. Fair value analysis shows that Ajanta Pharma’s stock is fairly valued in the market compared to other companies in the industry. It is important to also look at the historical performance of the company's stock price, which can be easily accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Balance Sheet

A company's balance sheet shows its financial health and is a key metric for investors to consider. Ajanta Pharma's financial statements reveal a healthy balance sheet with sound financial management. We offer our premium tool, DCF Analysis, which allows investors to determine the fair value of Ajanta Pharma’s stock based on the company's balance sheet.

Ajanta Pharma Ltd Annual Report

Investors can gain a deep understanding of Ajanta Pharma’s business model, financial performance, and growth prospects by studying its annual report. Ticker provides access to downloadable annual reports, which can then be studied to gain insight into the company's future plans and growth strategy.

Ajanta Pharma Ltd Dividend

Dividend payments by a company are an important source of returns for long-term investors. Ajanta Pharma has a track record of consistently paying a dividend to its shareholders. Investors can easily track the company's dividend history through Ticker's pre-built screening tool to make informed decisions.

Ajanta Pharma Ltd Quarterly Result

A company's quarterly results reflect its performance over a short period of time. Investors can use this information to note trends in the company's financial performance. Ticker provides access to Ajanta Pharma’s quarterly results as downloadable documents. Ticker premium tool, BVPS Analysis, can also be used to analyze the company's quarterly results and gain additional insights into the company's financial performance.

Ajanta Pharma Ltd Stock Price

A company's stock price can be influenced by numerous factors such as news, changes in market trends, or investor sentiment. Through Ticker, investors have access to accurate and real-time stock prices that can help them make informed decisions about buying or selling stocks.

Ajanta Pharma Ltd Price Chart

Price charts are an essential tool for traders and investors alike to track a company's stock performance over time. Ajanta Pharma’s stock price chart allows investors to analyze the movement of the stock price, helping them make tactical investment decisions.

Ajanta Pharma Ltd News and Concall

Keeping abreast of company news is crucial for investors to stay informed of any critical developments that could impact the company's performance. Ajanta Pharma's news and concall updates can be accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Transcripts and Investor Presentations

Transcripts and investor presentations provided by the company offer valuable insights into the company's operations, growth strategy, and performance. Ticker offers downloadable transcripts and investor presentations, allowing investors to track the company's progress.

Ajanta Pharma Ltd Promoters

Ajanta Pharma has a strong group of promoters focused on driving the company forward and creating value for shareholders. Ticker provides detailed information about the promoters of Ajanta Pharma, to help investors gain a better understanding of the company.

Ajanta Pharma Ltd Shareholders

Understanding the company's shareholders is key to understanding how the company is being managed. Investors can gain detailed insights into Ajanta Pharma's shareholders through ticker pre-built screening tool.

Ajanta Pharma Ltd ROCE

The Return on Capital Employed (ROCE) is a key financial ratio used to assess a company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides the ROCE data for Ajanta Pharma Ltd, enabling investors to evaluate the company's ability to generate returns on its capital employed. This ratio indicates the percentage of profit a company earns in relation to the total capital it has invested. Detailed information on Ajanta Pharma Ltd's ROCE can be found in the financials table or ratio section of our website.

Ajanta Pharma Ltd EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure used to assess a company's operational performance and profitability. Our stock analysis page offers the EBITDA data for Ajanta Pharma Ltd, allowing investors to analyze the company's earnings generated solely from its core business operations. By excluding non-operating expenses, EBITDA provides a clearer picture of a company's financial health. Access the detailed EBITDA figures for Ajanta Pharma Ltd in the financials table or ratio section on our website.

Ajanta Pharma Ltd DPS

DPS stands for Dividends Per Share, and it represents the portion of a company's profits distributed to its shareholders in the form of dividends. Our stock analysis page showcases the DPS data for Ajanta Pharma Ltd, allowing investors to monitor the dividend history and track the company's dividend payout ratio. Dividends are a crucial aspect of investment returns, and through our website, you can easily access the DPS information for Ajanta Pharma Ltd in the financials table or ratio section.

Ajanta Pharma Ltd EPS

EPS, or Earnings Per Share, is a widely used financial metric that measures the profitability of a company on a per-share basis. Our stock analysis page provides the EPS data for Ajanta Pharma Ltd, allowing investors to evaluate the company's profitability and track its earnings growth over time. EPS is an essential factor in determining a stock's valuation and potential returns. Detailed information on Ajanta Pharma Ltd's EPS can be found in the financials table or ratio section on our website.

Read More
X